vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Investar Holding Corp (ISTR). Click either name above to swap in a different company.
Investar Holding Corp is the larger business by last-quarter revenue ($23.5M vs $18.7M, roughly 1.3× CytomX Therapeutics, Inc.). On growth, Investar Holding Corp posted the faster year-over-year revenue change (0.9% vs -25.7%). Over the past eight quarters, Investar Holding Corp's revenue compounded faster (4.9% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Investar Holding Corp is a U.S.-headquartered bank holding company that primarily operates across the Gulf Coast region. It delivers a full range of commercial and retail banking services, including deposit products, consumer and business loans, mortgage services, and wealth management solutions for individual clients, small and medium-sized enterprises, and commercial entities.
CTMX vs ISTR — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $23.5M |
| Net Profit | $-154.0K | — |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 30.9% |
| Net Margin | -0.8% | — |
| Revenue YoY | -25.7% | 0.9% |
| Net Profit YoY | 97.6% | — |
| EPS (diluted) | — | $0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $23.5M | ||
| Q3 25 | — | $24.1M | ||
| Q2 25 | $18.7M | $22.3M | ||
| Q1 25 | $50.9M | $24.0M | ||
| Q4 24 | $38.1M | $23.3M | ||
| Q3 24 | $33.4M | $22.3M | ||
| Q2 24 | $25.1M | $20.4M | ||
| Q1 24 | $41.5M | $21.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | $6.2M | ||
| Q2 25 | $-154.0K | $4.5M | ||
| Q1 25 | $23.5M | $6.3M | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $5.4M | ||
| Q2 24 | $-6.5M | $4.1M | ||
| Q1 24 | $13.8M | $4.7M |
| Q4 25 | — | 30.9% | ||
| Q3 25 | — | 31.0% | ||
| Q2 25 | -6.9% | 24.4% | ||
| Q1 25 | 44.4% | 32.2% | ||
| Q4 24 | 46.4% | 31.1% | ||
| Q3 24 | 12.3% | 27.6% | ||
| Q2 24 | -33.7% | 24.0% | ||
| Q1 24 | 28.1% | 28.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | 25.6% | ||
| Q2 25 | -0.8% | 20.2% | ||
| Q1 25 | 46.2% | 26.3% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | 24.1% | ||
| Q2 24 | -26.0% | 19.9% | ||
| Q1 24 | 33.3% | 22.0% |
| Q4 25 | — | $0.50 | ||
| Q3 25 | — | $0.54 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.63 | ||
| Q4 24 | — | $0.61 | ||
| Q3 24 | — | $0.54 | ||
| Q2 24 | — | $0.41 | ||
| Q1 24 | — | $0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | — |
| Total DebtLower is stronger | — | $9.8M |
| Stockholders' EquityBook value | $119.9M | $301.1M |
| Total Assets | $175.1M | $2.8B |
| Debt / EquityLower = less leverage | — | 0.03× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | $9.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $9.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $301.1M | ||
| Q3 25 | — | $295.3M | ||
| Q2 25 | $119.9M | $255.9M | ||
| Q1 25 | $25.0M | $251.7M | ||
| Q4 24 | $-456.0K | $241.3M | ||
| Q3 24 | $-23.5M | $245.5M | ||
| Q2 24 | $-31.2M | $230.2M | ||
| Q1 24 | $-31.7M | $227.0M |
| Q4 25 | — | $2.8B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | $175.1M | $2.7B | ||
| Q1 25 | $98.5M | $2.7B | ||
| Q4 24 | $120.5M | $2.7B | ||
| Q3 24 | $139.0M | $2.8B | ||
| Q2 24 | $159.2M | $2.8B | ||
| Q1 24 | $184.7M | $2.8B |
| Q4 25 | — | 0.03× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $18.2M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $18.2M | ||
| Q3 25 | — | $6.9M | ||
| Q2 25 | $-15.8M | $3.2M | ||
| Q1 25 | $-21.0M | $4.5M | ||
| Q4 24 | $-19.9M | $15.9M | ||
| Q3 24 | $-20.7M | $5.6M | ||
| Q2 24 | $-19.5M | $2.8M | ||
| Q1 24 | $-26.0M | $7.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.12× | ||
| Q2 25 | — | 0.71× | ||
| Q1 25 | -0.89× | 0.71× | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | 1.03× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | -1.89× | 1.66× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
ISTR
Segment breakdown not available.
